Research & Development

Acepodia’s dual-payload antibody-drug conjugates can link multiple tumor-killing agents without antibody modification. Apart from a GPC3-targeting candidate, the Taiwan-US biotech is also working on a bispecific antibody ADC with two different payloads, its CEO tells Scrip in an interview.

XGene's pain candidate has shown positive results in a US bunionectomy trial and the Chinese company is also eyeing chronic and cancer pain indications for its contender, which may provide a competitor to Vertex's suzetrigine.

One month after announcing a pipeline pivot, Ovid Therapeutics talked to In Vivo about the importance of making strategic decisions with discipline, and the imminent neurology revolution.

Volleyball great Gabby Reece promotes Stemregen Sport; eye care pharma Harrow changes scientific lead; sisters partner to launch Renew-V vaginal moisturizer; Haleon tabs former Unilever executive as chief customer officer; and former Bayer executive leads Perrigo’s expanded scientific office.

Glen Clova Scientific is galvanizing virus-like particle technology with disruptive advances in manufacturing to treat immune-related dermatology conditions in often overlooked senile populations.

Two treatments that target elF2B, a regulator of the integrated stress response that appears to be overactive in the progressive motor neurone disease, have missed their primary and secondary endpoints in a landmark platform trial.

New alternative methods to animal testing in early drug development are increasing in sophistication and predictability, yet they are vastly underutilized. In Vivo presents an overview of select technologies and vendors.

Medtech Insight asked three leading AI experts, Verily’s Andrew Trister, Ferrum Health’s Pelu Tran and Hologic’s Jennifer Schneiders, to offer their perspectives on the future of AI in health care.

An artificial intelligence-based pathology tool for metabolic dysfunction-associated steatohepatitis shows promise for a drug development landscape that is said to be “fraught with trials that have shown borderline results or outright failures based on liver histology.”

The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.